The FDA cleared PrecivityAD2, a blood test designed to help evaluate Alzheimer’s disease by detecting amyloid pathology. Developed and validated from technology pioneered at Washington University School of Medicine in St. Louis, the test is positioned as an aid for clinicians assessing suspected cases where amyloid status informs next steps. Blood-based biomarkers are increasingly being developed to complement or reduce reliance on more invasive or costly approaches. With this clearance, PrecivityAD2 joins the growing set of tools aimed at improving patient selection for confirmatory testing and potential disease-modifying therapies. Commercialization could accelerate adoption if it proves practical in real-world workflows, particularly in settings where access to PET imaging or lumbar puncture remains limited.